Medical device developer BioVentrix (BVXX.US) is applying for an IPO in the United States, intending to raise $17 million.

Medical device company BioVentrix (BVXX.US), focused on the research and development of minimally invasive treatment technology for heart failure, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, intending to raise up to $17 million through an initial public offering (IPO). BioVentrix is a medical device company that develops and commercializes devices for treating heart failure with reduced ejection fraction (HFrEF). Its core product, the Revivent system, aims to restore left ventricular function in HFrEF patients with anterior wall scars from previous myocardial infarctions. The device uses titanium alloy anchor pins connected to PEEK bands to fold and reduce non-functional scar tissue in the left ventricle through minimally invasive surgery with small incisions. The surgery is performed while the heart is beating continuously, providing a less traumatic alternative to traditional intracardiac surgeries such as ventricular assist device implantation or heart transplants. BioVentrix had previously generated revenue by selling the Revivent TC Transcatheter Ventricular Enhancement System, which was discontinued in 2023 to save funds. Founded in 2003 and headquartered in Mansfield, Massachusetts, the company plans to list on the Nasdaq under the stock symbol BVXX. BioVentrix submitted its IPO application confidentially on August 5, 2025. The Benchmark Company is serving as the exclusive bookrunner for the IPO, and pricing terms have not yet been disclosed.